Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests01:27

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Atherosclerosis IV: Nursing Management01:23

Atherosclerosis IV: Nursing Management

Nursing management for a patient with arteriosclerosis involves a comprehensive approach focusing on lifestyle modification, disease monitoring, education, and symptomatic care. Here is an overview of effective nursing strategies:Assessment and Monitoring: Initial and ongoing assessments are crucial. Nurses must document the patient's medical history, including any hypertension, diabetes, hyperlipidemia, and other cardiovascular diseases. Assessments also cover family history and lifestyle...
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Age-associated B-cells predict coronary events in humans and aggravate murine atherosclerosis.

Cardiovascular research·2026
Same author

Photoplethysmography based remote cardiac blood pressure monitoring compared with 24-h ambulatory blood pressure monitoring.

Blood pressure monitoring·2026
Same author

Carotid plaque macrophage burden and inflammatory lipid-associated macrophage markers predict secondary major adverse cardiovascular events after endarterectomy.

European heart journal·2026
Same author

Decision-making when a child with haematological malignancy relapses following haematopoietic stem cell transplantation: A meta-ethnographic review.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer·2025
Same author

Assessment of photoplethysmography-based blood pressure determinations during long-term and short-term remote cardiac monitoring: the RECAMO study.

European heart journal. Digital health·2025
Same author

Bone Marrow Farnesoid X Receptor Deficiency Does Not Impact Atherosclerosis Susceptibility in Male Low-Density Lipoprotein Receptor Knockout Mice.

Arteriosclerosis, thrombosis, and vascular biology·2025

Related Experiment Video

Updated: Jun 27, 2026

Quantification of Atherosclerosis in Mice
06:59

Quantification of Atherosclerosis in Mice

Published on: June 12, 2019

Vaccination against TIE2 reduces atherosclerosis.

Arnaud D Hauer1, Kim L L Habets, Eva J A van Wanrooij

  • 1Division of Biopharmaceutics, Leiden University, 2333 CC, Leiden, The Netherlands. A.Hauer@LACDR.leidenuniv.nl

Atherosclerosis
|November 22, 2008
PubMed
Summary

DNA vaccination targeting TIE2-expressing cells successfully reduced atherosclerosis in mice. This approach induced cellular immunity, leading to smaller, more stable atherosclerotic lesions and reduced angiogenesis.

Related Experiment Videos

Last Updated: Jun 27, 2026

Quantification of Atherosclerosis in Mice
06:59

Quantification of Atherosclerosis in Mice

Published on: June 12, 2019

Area of Science:

  • Cardiovascular Research
  • Immunology
  • Vascular Biology

Background:

  • TIE2-expressing cells are integral to angiogenesis, a process implicated in atherosclerosis.
  • Targeting TIE2-expressing cells via DNA vaccination presents a potential strategy to modulate atherosclerosis development.

Purpose of the Study:

  • To investigate the efficacy of DNA vaccination targeting TIE2-expressing cells in reducing atherosclerosis.
  • To assess the impact of this vaccination strategy on cellular immunity, lesion size, plaque stability, and angiogenesis.

Main Methods:

  • An oral DNA vaccination technique using attenuated Salmonella typhimurium carrying plasmid pcDNA3.1 encoding TIE2 was employed in LDLr(-/-) mice.
  • Mice received three oral vaccinations before being placed on a Western-type diet to induce atherosclerosis.

Main Results:

  • Vaccination against TIE2 significantly reduced circulating TIE2(+) cells by 33%, confirming successful cellular immunity induction.
  • Significant reductions in carotid atherosclerosis (30% intima area, 27% intima/lumen ratio) and aortic root atherosclerosis (42%) were observed.
  • Adventitial angiogenesis decreased by 61%, and plaque collagen content increased (1.6-1.9 fold), indicating enhanced plaque stability.

Conclusions:

  • Vaccination against TIE2 effectively induces cellular immunity and attenuates atherosclerotic lesion development.
  • This vaccination strategy promotes a more stable plaque phenotype and may offer a novel therapeutic approach for atherosclerosis.